Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RPG Life SciencesNSE:RPGLIFE -1.89%88 Return-on-Tangible-Equity is 20.03% as of Mar. 2026, which is 19% below its 10-year median of 24.68. GuruFocus rates NSE:RPGLIFE with a GF Score™ of 88/100 and a GF Value™ of ₹2,360.73 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 901 Drug Manufacturers companies, RPG Life Sciences ranks better than 80.47% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. RPG Life Sciences's annualized net income for the quarter that ended in Mar. 2026 was ₹1,196 Mil. RPG Life Sciences's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹5,972 Mil. Therefore, RPG Life Sciences's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 20.03%.
The historical rank and industry rank for RPG Life Sciences's Return-on-Tangible-Equity or its related term are showing as below:
NSE:RPGLIFE'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 10.38 Med: 24.68 Max: 42.88
Current: 21.08
During the past 13 years, RPG Life Sciences's highest Return-on-Tangible-Equity was 42.88%. The lowest was 10.38%. And the median was 24.68%.
NSE:RPGLIFE's Return-on-Tangible-Equity is ranked better than 80.47% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs NSE:RPGLIFE: 21.08
RPG Life Sciences (NSE:RPGLIFE) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
RPG Life Sciences Return-on-Tangible-Equity Related Terms
RPG Life Sciences Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for RPG Life Sciences's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:RPGLIFE vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, RPG Life Sciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RPG Life Sciences Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, RPG Life Sciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where RPG Life Sciences's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 20.03% mean?
RPG Life Sciences (NSE:RPGLIFE) has a Return-on-Tangible-Equity of 20.03% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on RPG Life Sciences and its competitors. This is 19% below median its historical median of 24.68. Over the past decade, RPG Life Sciences' Return-on-Tangible-Equity has ranged from 10.38 to 42.88. According to the industry distribution chart, RPG Life Sciences ranks #176 out of 901 companies in the Drug Manufacturers industry, placing it in the top 19.5%.
Is RPG Life Sciences' Return-on-Tangible-Equity too high?
RPG Life Sciences' current Return-on-Tangible-Equity of 20.03% is 19% below median its 10-year median of 24.68. Over the past 10 years, this metric has ranged from a low of 10.38 to a high of 42.88. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. RPG Life Sciences' value of 20.03% is 153.5% above this industry median. Based on the distribution chart, RPG Life Sciences ranks #176 out of 901 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, RPG Life Sciences has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RPG Life Sciences' Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, RPG Life Sciences ranks #176 out of 901 companies for Return-on-Tangible-Equity. This places RPG Life Sciences in the top 20% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.90. RPG Life Sciences' value of 20.03% is 153.5% above this benchmark. Historically, RPG Life Sciences' own Return-on-Tangible-Equity has ranged from 10.38 to 42.88 over the past decade. While the company's 10-year median is 24.68 vs. the industry median of 7.90, RPG Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RPG Life Sciences's current Return-on-Tangible-Equity of 20.03% is 153.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on RPG Life Sciences and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RPG Life Sciences's current Return-on-Tangible-Equity is 20.03%, which is 19% below median its own 10-year median of 24.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RPG Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RPG Life Sciences (NSE:RPGLIFE) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,360.73, compared to a current price of ₹2,921.90 — trading 23.8% above its estimated fair value. The current Return-on-Tangible-Equity is 20.03%, which is 19% below median its 10-year median of 24.68 and 153.5% above the Drug Manufacturers industry median of 7.90. RPG Life Sciences' overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For RPG Life Sciences (NSE:RPGLIFE), the current Return-on-Tangible-Equity is 20.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RPG Life Sciences (NSE:RPGLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, RPG Life Sciences stock appears to be overvalued.
The current stock price of ₹2,921.90 is trading 23.8% above its estimated GF Value™ of ₹2,360.73.
GuruFocus considers RPG Life Sciences to be Modestly Overvalued.
Key valuation signals for NSE:RPGLIFE:
Return-on-Tangible-Equity: 20.03% (19% below median its 10-year median of 24.68)
GF Value™: ₹2,360.73 vs. price of ₹2,921.90 (23.8% above fair value)
Industry Position: 153.5% above the Drug Manufacturers median (#176 of 901)
No single metric tells the full story. See the NSE:RPGLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RPG Life Sciences Ltd is an integrated pharmaceutical company. Its only reportable segment is the manufacturing and marketing of pharmaceutical products. Geographically, it derives a majority of revenue from India. The company operates across Domestic Formulations, International Formulations and Active Pharmaceutical Ingredients (API). It focuses on Nephrology, Oncology, Urology, Respiratory, Gastrointestinal, Cardiovascular, Gynaecology and Pediatrics, Vitamins and Minerals, Pain Management, Neurology, Anti-Dengue, Anti-Diabetic, and Derma.
88GF Score
Get the complete analysis for NSE:RPGLIFE
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:RPGLIFE has been successfully added to your 
